• Select the area you would like to search.
  • ACTIVE INVESTIGATIONS Search for current projects using the investigator's name, institution, or keywords.
  • EXPERTS KNOWLEDGE BASE Enter keywords to search a list of questions and answers received and processed by the ADNI team.
  • ADNI PDFS Search any ADNI publication pdf by author, keyword, or PMID. Use an asterisk only to view all pdfs.


Lewy body pathology is detected in CSF of ADNI individuals spanning the AD spectrum
Wed, May 22, 2024

Link to article: https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.13858

Lewy body (LB) co-pathology was investigated in individuals with AD pathology in the ADNI clinical cohort. The α-synuclein seed amplification assay (SAA) was performed on recent samples of CSF which included participants who were diagnosed across the AD spectrum. This study confirmed sensitivity (79%) and specificity (97%) of SAA in detecting LB pathology in comparison to gold-standard autopsy. SAA positivity (SAA+) was detected in 22% of the ADNI cohort, and increased with age and disease stage. Increased SAA+ prevalence was associated with greater Ab burden, lower tau burden (particularly in Dementia participants), and cognitive impairment. This study expands our understanding of utilizing the α-synuclein SAA to asses LB co-pathology in AD, and broadens the clinical lens to better guide diagnostic and therapeutic approaches to AD.

This post was written by: - who has written 70 posts on ADNI.

Comments are closed.